E0200 |
Trastuzumab-deruxtecan (DS-8201a, T-DXd)
|
Trastuzumab deruxtecan (DS-8201a, T-DXd) is an antibody-drug conjugate (ADC) composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody and a cytotoxic topoisomerase I inhibitor. Trastuzumab deruxtecan shows durable antitumor activity. Trastuzumab deruxtecan has a molecular weight of 153KDa. This product is supplied as 10mg/ml PBS solution.This product is discontinued. We recommend the replacement products: D4001. |
|
|
D4006New |
Anetumab-MMAE
|
Anetumab-MMAE is an antibody-drug conjugate (ADC) composed of a human anti-mesothelin (MSLN) antibody and the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). |
|
|
D4011New |
Anetumab ravtansine
|
Anetumab ravtansine (BAY 94-9343) is an antibody-drug conjugate (ADC) composed of a human anti-mesothelin antibody and a cytotoxic maytansinoid tubulin inhibitor DM4. Anetumab ravtansine has the potential to treat advanced solid tumors. |
|
|
D4019New |
Sirtratumab vedotin
|
Sirtratumab Vedotin (ASG-15ME), is an antibody-drug conjugate (ADC) composed of SLTRK6 (SLIT and NTRK like family member 6, "SLIT and NTRK-like family, member 6") and cytotoxic agent monomethyl auristatin E (MMAE). It delivers a small molecule microtubule-disrupting agent, monomethyl auristatin E (MMAE), to tumor cells expressing SLITRK6. SIRTRATUMAB VEDOTIN has the potential for Bladder Cancer, Metastatic urothelial cancer research. |
|
|
D4026New |
Tusamitamab ravtansine
|
Tusamitamab Ravtansine (SAR-408701), is an antibody-drug conjugate (ADC) composed of CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule ) targeting antibody and a cytotoxic maytansinoid tubulin inhibitor DM4. TUSAMITAMAB RAVTANSINE has the potential for use in research of several solid tumors. |
|
|
E2841 |
Sacituzumab-govitecan
|
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38, showing anticancer activity. Sacituzumab govitecan has a molecular weight of 160KDa. This product is supplied as 10mg/ml PBS solution.This product is discontinued. We recommend the replacement products: D4002. |
|
|
E2851 |
Trastuzumab-Emtansine(T-DM1)
|
Trastuzumab Emtansine(T-DM1,Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1.Trastuzumab emtansine has a molecular weight of 145kDa.This product is supplied as 10mg/ml PBS solution. This product is discontinued. We recommend the replacement products: D4003 |
|
|
D4048New |
Labetuzumab govitecan
|
Labetuzumab govitecan (IMMU-135) is a humanised anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody linked site-specifically to the active metabolite of irinotecan SN-38 via a proprietary linker. Labetuzumab govitecan can be used for research on colorectal cancer. |
|
|
D4050New |
Datopotamab deruxtecan
|
Datopotamab deruxtecan (DS-1062, DS-1062A, Anti-TRP2/dxd) is an antibody-drug conjugate (ADC) composed of a humanized anti-TROP2 monoclonal antibody, conjugated to topoisomerase I inhibitor, via a tetrapeptide-based linker. Datopotamab deruxtecan has the potential for use in solid tumors mainly in advanced unresectable advanced NSCLC. |
|
|
D4053New |
Enfortumab vedotin-ejfv
|
Enfortumab vedotin-ejfv (Padcev) is an antibody-drug conjugate (ADC) composed of an fully human anti-Nectin-4 IgG1 kappa monoclonal antibody (AGS-22C3), conjugated to Monomethyl Auristatin E (MMAE), via a protease-cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl. Enfortumab vedotin-ejfv has the potential for use in research of urothelial carcinoma. |
|
|
D4057New |
Ladiratuzumab vedotin
|
Ladiratuzumab vedotin (SGN-LIV1A, Anti-LIV-1 ADC) is an antibody-drug conjugate (ADC) composed of humanized anti-LIV-1 antibody, conjugated to Monomethyl auristatin E (MMAE), via a proteolytically cleavable type linker. Ladiratuzumab vedotin has the potential for use in multiple carcinomas. |
|
|
D4006New |
Anetumab-MMAE
|
Anetumab-MMAE is an antibody-drug conjugate (ADC) composed of a human anti-mesothelin (MSLN) antibody and the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). |
|
|
D4011New |
Anetumab ravtansine
|
Anetumab ravtansine (BAY 94-9343) is an antibody-drug conjugate (ADC) composed of a human anti-mesothelin antibody and a cytotoxic maytansinoid tubulin inhibitor DM4. Anetumab ravtansine has the potential to treat advanced solid tumors. |
|
|
D4019New |
Sirtratumab vedotin
|
Sirtratumab Vedotin (ASG-15ME), is an antibody-drug conjugate (ADC) composed of SLTRK6 (SLIT and NTRK like family member 6, "SLIT and NTRK-like family, member 6") and cytotoxic agent monomethyl auristatin E (MMAE). It delivers a small molecule microtubule-disrupting agent, monomethyl auristatin E (MMAE), to tumor cells expressing SLITRK6. SIRTRATUMAB VEDOTIN has the potential for Bladder Cancer, Metastatic urothelial cancer research. |
|
|
D4026New |
Tusamitamab ravtansine
|
Tusamitamab Ravtansine (SAR-408701), is an antibody-drug conjugate (ADC) composed of CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule ) targeting antibody and a cytotoxic maytansinoid tubulin inhibitor DM4. TUSAMITAMAB RAVTANSINE has the potential for use in research of several solid tumors. |
|
|
E2851 |
Trastuzumab-Emtansine(T-DM1)
|
Trastuzumab Emtansine(T-DM1,Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1.Trastuzumab emtansine has a molecular weight of 145kDa.This product is supplied as 10mg/ml PBS solution. This product is discontinued. We recommend the replacement products: D4003 |
|
|
D4048New |
Labetuzumab govitecan
|
Labetuzumab govitecan (IMMU-135) is a humanised anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody linked site-specifically to the active metabolite of irinotecan SN-38 via a proprietary linker. Labetuzumab govitecan can be used for research on colorectal cancer. |
|
|
D4050New |
Datopotamab deruxtecan
|
Datopotamab deruxtecan (DS-1062, DS-1062A, Anti-TRP2/dxd) is an antibody-drug conjugate (ADC) composed of a humanized anti-TROP2 monoclonal antibody, conjugated to topoisomerase I inhibitor, via a tetrapeptide-based linker. Datopotamab deruxtecan has the potential for use in solid tumors mainly in advanced unresectable advanced NSCLC. |
|
|
D4053New |
Enfortumab vedotin-ejfv
|
Enfortumab vedotin-ejfv (Padcev) is an antibody-drug conjugate (ADC) composed of an fully human anti-Nectin-4 IgG1 kappa monoclonal antibody (AGS-22C3), conjugated to Monomethyl Auristatin E (MMAE), via a protease-cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl. Enfortumab vedotin-ejfv has the potential for use in research of urothelial carcinoma. |
|
|
D4057New |
Ladiratuzumab vedotin
|
Ladiratuzumab vedotin (SGN-LIV1A, Anti-LIV-1 ADC) is an antibody-drug conjugate (ADC) composed of humanized anti-LIV-1 antibody, conjugated to Monomethyl auristatin E (MMAE), via a proteolytically cleavable type linker. Ladiratuzumab vedotin has the potential for use in multiple carcinomas. |
|
|
D4006New |
Anetumab-MMAE
|
Anetumab-MMAE is an antibody-drug conjugate (ADC) composed of a human anti-mesothelin (MSLN) antibody and the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). |
|
|
D4011New |
Anetumab ravtansine
|
Anetumab ravtansine (BAY 94-9343) is an antibody-drug conjugate (ADC) composed of a human anti-mesothelin antibody and a cytotoxic maytansinoid tubulin inhibitor DM4. Anetumab ravtansine has the potential to treat advanced solid tumors. |
|
|
D4019New |
Sirtratumab vedotin
|
Sirtratumab Vedotin (ASG-15ME), is an antibody-drug conjugate (ADC) composed of SLTRK6 (SLIT and NTRK like family member 6, "SLIT and NTRK-like family, member 6") and cytotoxic agent monomethyl auristatin E (MMAE). It delivers a small molecule microtubule-disrupting agent, monomethyl auristatin E (MMAE), to tumor cells expressing SLITRK6. SIRTRATUMAB VEDOTIN has the potential for Bladder Cancer, Metastatic urothelial cancer research. |
|
|
D4026New |
Tusamitamab ravtansine
|
Tusamitamab Ravtansine (SAR-408701), is an antibody-drug conjugate (ADC) composed of CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule ) targeting antibody and a cytotoxic maytansinoid tubulin inhibitor DM4. TUSAMITAMAB RAVTANSINE has the potential for use in research of several solid tumors. |
|
|
D4048New |
Labetuzumab govitecan
|
Labetuzumab govitecan (IMMU-135) is a humanised anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody linked site-specifically to the active metabolite of irinotecan SN-38 via a proprietary linker. Labetuzumab govitecan can be used for research on colorectal cancer. |
|
|
D4050New |
Datopotamab deruxtecan
|
Datopotamab deruxtecan (DS-1062, DS-1062A, Anti-TRP2/dxd) is an antibody-drug conjugate (ADC) composed of a humanized anti-TROP2 monoclonal antibody, conjugated to topoisomerase I inhibitor, via a tetrapeptide-based linker. Datopotamab deruxtecan has the potential for use in solid tumors mainly in advanced unresectable advanced NSCLC. |
|
|
D4053New |
Enfortumab vedotin-ejfv
|
Enfortumab vedotin-ejfv (Padcev) is an antibody-drug conjugate (ADC) composed of an fully human anti-Nectin-4 IgG1 kappa monoclonal antibody (AGS-22C3), conjugated to Monomethyl Auristatin E (MMAE), via a protease-cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl. Enfortumab vedotin-ejfv has the potential for use in research of urothelial carcinoma. |
|
|
D4057New |
Ladiratuzumab vedotin
|
Ladiratuzumab vedotin (SGN-LIV1A, Anti-LIV-1 ADC) is an antibody-drug conjugate (ADC) composed of humanized anti-LIV-1 antibody, conjugated to Monomethyl auristatin E (MMAE), via a proteolytically cleavable type linker. Ladiratuzumab vedotin has the potential for use in multiple carcinomas. |
|
|